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status and, importantly, at an ultrahigh 
dose, increased GSH and GSH/GSSG ratio 
to values comparable to those estimated in 
normotensive WKY rats. A greater increase 
in GSH/GSSG ratio also significantly cor-
related with a greater reduction in NF-κB 
activation and interstitial infiltrates.2
Normalization of redox state by an ultra-
high dose of Cand is particularly relevant 
if we consider that, as opposed to normo-
tensive WKY rats, SHRs fail to upregulate 
the antioxidant defense as a compensatory 
mechanism to increased oxidative stress.
In line with the data of Chen et al.,2 pre-
vious studies have documented infiltra-
tion of inflammatory lymphocytes and 
macrophages into the renal parenchyma 
of SHRs that can be reduced by the anti-
oxidant melatonin.9 This treatment also 
improved hypertension. It is likely that 
inflammatory cells present in the intersti-
tium contribute to hypertension in SHRs 
by promoting local Ang II production and 
oxidative stress.
The anti-inflammatory effect of Cand 
has been previously investigated in SHRs 
in relation to hypertension-induced 
atherosclerosis in this model. Cand was 
shown to reduce the expression of vascular 
inflammatory cytokines to a greater extent 
than hypertensive triple therapy (hydrala-
zine, hydrochlorothiazide, and reserpine) 
despite comparable blood pressure con-
trol.12 Consistently, only Cand downregu-
lated NF-κB p50 subunit precursor p105, 
suggesting that the anti-inflammatory 
effect of Cand is beyond blood pressure 
reduction and that AT1R partly contrib-
utes to NF-κB activation at least in blood 
vessels. In light of the paper by Chen et al.,2 
one may expect superior protective effects 
of ultrahigh dosage of Cand on vascular 
disease, independently of AT1R.
In patients with chronic kidney disease, 
a double-blind, randomized, prospective 
study has recently documented an addi-
tional antiproteinuric effect of an ultrahigh 
dose of Cand compared with a standard 
dose.13 Whether the antiproteinuric effect 
translates into a slower rate of renal and 
cardiovascular end points has not been 
studied but can be speculated.
In the meantime, further experiments 
should prove the real benefit of ultrahigh 
dosage of Cand in comparison with stand-
ard dosage of Cand used alone or combined 
with an ACE inhibitor for chronic renal 
inflammation. This would support the 
rationale to test ultrahigh dosage of Cand, 
possibly targeted to oxidative stress, in the 
context of multiple drug treatment to induce 
remission of chronic kidney disease.
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The article by Finkelstein and colleagues is a seminal work in helping us 
to understand the educational needs of pre–end-stage renal disease 
(pre-ESRD) patients. There are currently major deficits in patients’ 
perceived knowledge of their options for ESRD care. The Canadian 
system, with its more integrated and multidisciplinary approach to care, 
does a better job of communicating these options to patients. African 
Americans are less likely to be aware of their options. 
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In this issue of Kidney International, 
Finkelstein and colleagues1 point out 
that patients’ perceived knowledge of their 
options for treatment in end-stage renal 
disease (ESRD) is limited. The authors 
also note that patient choice is the major 
factor in choosing a dialysis therapy as 
patients approach ESRD. Thus, patients’ 
perceived lack of knowledge can have a 
major impact on treatment. This work is 
2: 902–912.
7. Brezniceanu ML, Liu F, Wei CC et al. Catalase 
overexpression attenuates angiotensinogen 
expression and apoptosis in diabetic mice. Kidney 
Int 2007; 71: 912–923.
8. Zhan CD, Sindhu RK, Vaziri ND. Up-regulation of 
kidney NAD(P)H oxidase and calcineurin in SHR: 
reversal by lifelong antioxidant supplementation. 
Kidney Int 2004; 65: 219–227.
9. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. 
Melatonin reduces renal interstitial inflammation 
and improves hypertension in spontaneously 
hypertensive rats. Am J Physiol Renal Physiol 2003; 
284: F447–F454.
10. Adler S, Huang H. Oxidant stress in kidneys of 
spontaneously hypertensive rats involves both 
oxidase overexpression and loss of extracellular 
superoxide dismutase. Am J Physiol Renal Physiol 
2004; 287: F907–F913.
11. Wilcox CS. Oxidative stress and nitric oxide 
deficiency in the kidney: a critical link to 
hypertension? Am J Physiol Regul Integr Comp 
Physiol 2005; 289: R913–R935.
12. Sanz-Rosa D, Oubina MP, Cediel E et al. Effect of AT1 
receptor antagonism on vascular and circulating 
inflammatory mediators in SHR: role of NF-kappaB/
IkappaB system. Am J Physiol Heart Circ Physiol 2005; 
288: H111–H115.
13. Schmieder RE, Klingbeil AU, Fleischmann EH et 
al. Additional antiproteinuric effect of ultrahigh 
dose candesartan: a double-blind, randomized, 
prospective study. J Am Soc Nephrol 2005; 16: 
3038–3045.
Kidney International (2008) 74          1115
commentar y
particularly significant for two reasons. 
First, it demonstrates that it is not just 
lack of early referral to nephrologists that 
is causing this educational deficit. In this 
study, the average time under specialty 
care was 5.2 years. Second, the authors 
begin to define areas where future work 
is needed. This study has implications 
for how we both design and finance pre-
ESRD care.
The chronic care model, as defined by 
Ed Wagner and colleagues, demonstrates 
that we need both prepared proactive 
practice teams and informed activated 
patients. A productive interaction is 
required between these two to improve 
clinical outcomes (Figure 1).2 The arti-
cle by Finkelstein et al.1 begins to show 
us how we can do a better job informing 
patients. Having an adequate number of 
nephrologists is not enough. A multi-
disciplinary team-including dieticians, 
social workers, nurse educators, and 
pharmacists-and access to transplant 
surgeons are necessary to improve patient 
knowledge and understanding about pro-
gression of chronic kidney disease (CKD) 
and treatment options.
In addition, policy change that allows 
for reimbursement of these services, as 
well as for increased physician time per 
visit, is necessary if we are to have a truly 
informed patient. There is currently leg-
islation before the United States Congress 
that would support this kind of initiative. 
Bills have been introduced in the Senate by 
Sens. Blanche Lincoln and Susan Collins 
(S. 432) and in the House by Reps. Mark 
Kirk and Jim McDermott (H.R. 1245) to 
establish a predialysis education benefit. 
In addition, the Kidney Care Quality and 
Education Act of 2007 (S. 691; H.R. 1193) 
includes a provision for a similar Medicare 
predialysis education benefit.
Finkelstein et al.1 demonstrated that 35% 
of patients with pre-ESRD had no knowl-
edge about any therapeutic modality for 
ESRD. Forty-three percent had no knowl-
edge of hemodialysis, 57% of continuous 
ambulatory peritoneal dialysis, 66% of 
automated peritoneal dialysis, and 56% of 
transplantation. When patients were strati-
fied by frequency of nephrology visits and 
stage of CKD, their knowledge about these 
treatment modalities improved. This sug-
gests that only when the patient’s condition 
worsens do knowledge and understanding 
of kidney disease improve, presumably 
because of increased contact with neph-
rologists. In addition, it was noted that in 
the Canadian system, where there is a more 
integrated approach to dialysis and CKD 
care, there was better perceived knowledge 
of treatment options. This again speaks to 
the importance of having the financial 
resources and necessary infrastructure for 
a multidisciplinary educational approach 
for patients with CKD.
This study also demonstrated that Afri-
can Americans were less likely than either 
white or Asian patients to have adequate 
knowledge to make informed treatment 
decisions regarding hemodialysis, peri-
toneal dialysis, and transplantation. This 
is an important health disparity issue. 
It takes on even greater import because 
African Americans are much more likely 
to suffer from CKD.3 Issues of health lit-
eracy and cultural competency need to be 
addressed as we design pre-ESRD care for 
this vulnerable population.
The study by Finkelstein et al.1 has sig-
nificant weaknesses. It should be noted 
that this is perceived knowledge, not 
actual knowledge. Also, the study had a 
very low response rate of 29.4%. Eighty-
six percent of these responses were from 
Canadian patients, and less than 5% were 
from African American patients. In addi-
tion, most of the participating centers 
were prominent university medical cent-
ers in major cities in both Canada and 
the United States. The findings of this 
study may not be generalizable to small 
communities or to rural locales. These 
findings would need to be confirmed in 
larger studies and in different populations 
to be considered generalizable. Despite 
that, there is very little information about 
patient factors and knowledge in the cur-
rent literature, which makes this a good 
first effort.
What can we learn from all this? First 
of all, we need to do a better job of under-
standing and addressing what our patients 
know about their treatment options 
regarding renal replacement thereapy. 
Second, it is important to have a multi-
disciplinary support team, including 
nurse educators, social workers, dieti-
cians, and pharmacists, that is integral to 
this care. Finally, issues of health literacy 
and developing a culturally competent 
message need to be addressed to improve 
care to our African American patients and 
to reduce health disparities.
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Figure 1 | The chronic care model developed by Ed Wagner and the Group Health Cooperative of 
Puget Sound. PCP, primary care physician.
